Aeglea BioTherapeutics | Investor Presentation Deck | 33 slides

Aeglea BioTherapeutics · 2022-02
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

6
coverage by narrative range · generated from this deck JSON

Slide inventory

33
every slide · same image gating as the playbook
01
Slide 1
front_matter
03
front_matter
04
front_matter
05
front_matter
06
frame_problem
Open slide detailBeat · Problem Statement
07
frame_problem
Open slide detailBeat · Problem Statement
08
diagnose_problem
Open slide detailBeat · Key Messages
09
front_matter
10
The slide uses a narrative structure to outline the patient's clinical progression from birth to genetic diagnosis.illustrate_case
Open slide detailBeat · Patient Medical History
11
The slide uses a timeline framework to map clinical events against age in years.diagnose_problem
Open slide detailBeat · Patient Medical History
12
The slide uses a narrative structure to explain the diagnostic journey from initial symptoms to definitive genetic confirmation.diagnose_problem
13
The slide uses a before-after framework to demonstrate the efficacy of the treatment plan.diagnose_problem
Open slide detailBeat · Diagnostic Methods and Biochemistry Labs
14
The chart tracks patient data from 2007 to 2021 with specific clinical annotations explaining fluctuations.analyze_data
15
Clinical case study summary slide.summarize
16
summarize
Open slide detailBeat · Summary and Conclusions
17
The slide uses a vertical icon-based process flow to connect clinical facts to the conclusion.diagnose_problem
Open slide detailLoop · Cost Of Inaction
18
summarize
19
front_matter
20
Includes patient photo and clinical data table comparing normal ranges to patient baseline.diagnose_problem
21
The chart is a box plot showing arginine levels over time, with reference lines for normal and target ranges.analyze_data
Open slide detailBeat · Pegzilarginase Program OverviewLoop · Jobs To Be Done
22
The slide uses a process flow diagram to illustrate the clinical trial structure.present_framework
Open slide detailLoop · Jobs To Be Done
23
The slide uses a combination of medical classification (GMFCS) and functional assessment tools (GMFM, Timed Walk Tests) to quantify mobility.present_framework
Open slide detailLoop · Jobs To Be Done
24
Clinical trial safety data presentation.analyze_data
Open slide detailLoop · Jobs To Be Done
25
The chart uses box plots to show distribution, with specific clinical guideline and normal range thresholds marked.analyze_data
Open slide detailLoop · Jobs To Be Done
26
The slide highlights the efficacy of pegzilarginase in a clinical setting.analyze_data
Open slide detailLoop · Jobs To Be Done
27
Includes MCID thresholds for GMFM-E (GMFCS I and II).analyze_data
28
Includes study design timeline and MCID thresholds for GMFCS levels.analyze_data
29
Includes patient photos as visual evidence of mobility improvement.summarize
30
summarize
31
The photo shows a child with a sign that says 'First Day of 4th GRADE' and 'I WANT TO BE A: WARRIOR SEPT. 1st 2021'.introduce_nominees
32
summarize
33
Contains company logo, address, website, and document reference code.front_matter